® Consulta de Marcas Base do INPI · pesquisa e monitoramento

biohaven pharmaceuticals

Registro de marca em vigor (Madri)

Marca Mista depositada no INPI em 14/12/2021 por Biohaven Therapeutics Ltd., processo nº 501650146, nas classes 05, 42. Registro em vigor até 14/12/2031.

Número do processo501650146
SituaçãoRegistro de marca em vigor (Madri)
ApresentaçãoMista
NaturezaMadri Produto/Serviço
Data do depósito14/12/2021
Data da concessão08/04/2025
Vigência até14/12/2031
TitularBiohaven Therapeutics Ltd.
CNPJ/CPF do titular
UF · País— · VG

Apostila: "PHARMACEUTICALS"

Classes e especificação

Classe 05 — Farmacêuticos e saúde

Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in Amyotrophic Lateral Sclerosis (ALS), pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in Alzheimer's disease (AD), disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine for the adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use.;

Classe 42 — Tecnologia e pesquisa

Pharmaceutical research and development in the fields of headache, facial pain, impulse control disorders, neurological disorders, and neurodegenerative disorders, and consultation provided in conjunction therewith.;

Acompanhe este processo

Receba um e-mail a cada novo despacho publicado na RPI para o processo 501650146 — exigência, oposição, deferimento, prazo de pagamento — e quando alguém depositar uma marca parecida.

Monitorar esta marca Ver marcas parecidas

Andamento do processo no INPI

6 despacho(s) publicado(s) na Revista da Propriedade Industrial.

  1. 08/04/2025 Concessão de registro em designação código IPAS770 · RPI 2831
  2. 25/02/2025 Recurso provido (decisão reformada para: Deferimento) <b>Protocolo:</b> 850230209617 (08/05/2023) <br /> <b>Petição (tipo):</b> Recurso contra indeferimento de pedido de registro de marca (3000.1)<br /><b>Requerente: </b>BIOHAVEN THERAPEUTICS LTD.<br /><b>Procurador: </b>Rodrigo Affonso de Ouro Preto Santos<br /> código IPAS237 · RPI 2825
  3. 03/09/2024 Notificação de recurso <b>Protocolo:</b> 850230209617 (08/05/2023) <br /> <b>Petição (tipo):</b> Recurso contra indeferimento de pedido de registro de marca (3000.1)<br /><b>Requerente: </b>BIOHAVEN THERAPEUTICS LTD.<br /><b>Procurador: </b>Rodrigo Affonso de Ouro Preto Santos<br /><b>Detalhes do despacho:</b>Recurso contra deferimento parcial.<br /> código IPAS360 · RPI 2800
  4. 18/06/2024 Anotação de alteração de nome e/ou endereço em designação <b>Protocolo:</b> 1704303101 (17/04/2023) <br /> <b>Petição (tipo):</b> Protocolo de Madri - NEWNAME<br /><b>Detalhes do despacho:</b>Sede alterada.<br /> código IPAS900 · RPI 2789
  5. 07/03/2023 Deferimento parcial de designação <b>Detalhes do despacho: </b>A marca reproduz ou imita os seguintes registros de terceiros, sendo, portanto, irregistrável de acordo com o inciso XIX do Art. 124 da LPI. As anterioridades impeditivas identificadas na busca realizada em cada classe do pedido são as seguintes: NCL(11-0)5: Processo 917194470 (HAVEN), Processo 917205120 (HAVEN). Art. 124 - Não são registráveis como marca: XIX - reprodução ou imitação, no todo ou em parte, ainda que com acréscimo, de marca alheia registrada, para distinguir ou certificar produto ou serviço idêntico, semelhante ou afim, suscetível de causar confusão ou associação com marca alheia; código IPAS781 · RPI 2722
  6. 10/05/2022 Publicação de pedido de registro para oposição (exame formal de designação concluído) código IPAS756 · RPI 2679

Outras marcas de Biohaven Therapeutics Ltd.

Classificação figurativa (Viena)